Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Cichocki

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Neuro-Oncology|July 11, 2026
iPSC-derived NK cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engagerJian-Fang Ning, Zachary B Davis, Qudsia Zeb, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2015
Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell TransplantationZachary B Davis, Sarah A Cooley, Frank Cichocki, et al.
Cancer Research|August 10, 2017
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor ActivityFrank Cichocki, Bahram Valamehr, Ryan Bjordahl, et al.
Science Translational Medicine|July 19, 2023
Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphomaFrank Cichocki, Bin Zhang, Cheng-Ying Wu, et al.
Cancer Research Communications|January 28, 2025
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic TargetingJohn R Lozada, Andrew Elliott, Mark G Evans, et al.
Science Translational Medicine|November 5, 2020
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapyFrank Cichocki, Ryan Bjordahl, Svetlana Gaidarova, et al.
Nature Communications|November 29, 2022
Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myelomaFrank Cichocki, Ryan Bjordahl, Jodie P Goodridge, et al.
Blood|August 26, 2025
Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiencyJacob Myers, Rih-Sheng Huang, Shee Kwan Phung, et al.
Science Immunology|March 13, 2021
The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiationTim D Holmes, Ram Vinay Pandey, Eric Y Helm, et al.
Nature Immunology|July 2, 2024
High-dimensional single-cell analysis of human natural killer cell heterogeneityLucas Rebuffet, Janine E Melsen, Bertrand Escalière, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Neuro-Oncology|July 11, 2026
iPSC-derived NK cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engagerJian-Fang Ning, Zachary B Davis, Qudsia Zeb, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2015
Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell TransplantationZachary B Davis, Sarah A Cooley, Frank Cichocki, et al.
Cancer Research|August 10, 2017
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor ActivityFrank Cichocki, Bahram Valamehr, Ryan Bjordahl, et al.
Science Translational Medicine|July 19, 2023
Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphomaFrank Cichocki, Bin Zhang, Cheng-Ying Wu, et al.
Cancer Research Communications|January 28, 2025
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic TargetingJohn R Lozada, Andrew Elliott, Mark G Evans, et al.
Science Translational Medicine|November 5, 2020
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapyFrank Cichocki, Ryan Bjordahl, Svetlana Gaidarova, et al.
Nature Communications|November 29, 2022
Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myelomaFrank Cichocki, Ryan Bjordahl, Jodie P Goodridge, et al.
Blood|August 26, 2025
Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiencyJacob Myers, Rih-Sheng Huang, Shee Kwan Phung, et al.
Science Immunology|March 13, 2021
The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiationTim D Holmes, Ram Vinay Pandey, Eric Y Helm, et al.
Nature Immunology|July 2, 2024
High-dimensional single-cell analysis of human natural killer cell heterogeneityLucas Rebuffet, Janine E Melsen, Bertrand Escalière, et al.
Pageof 7